Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Pat...
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177 Lu-PSMA-617 Radioligand Therapy
About this item
Full title
Author / Creator
Publisher
Australia
Journal title
Language
English
Formats
Publication information
Publisher
Australia
Subjects
More information
Scope and Contents
Contents
Lu-177-PSMA-617 radioligand therapy (RLT) is currently under approval for treatment of metastatic castration resistant prostate cancer (mCRPC) patients with late stage disease. However, previous studies demonstrated both heterogeneity of prostate specific membrane antigen (PSMA) expression, as well as response to PSMA treatment among mCRPC patients...
Alternative Titles
Full title
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177 Lu-PSMA-617 Radioligand Therapy
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_crossref_primary_10_7150_thno_44556
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_crossref_primary_10_7150_thno_44556
Other Identifiers
ISSN
1838-7640
E-ISSN
1838-7640
DOI
10.7150/thno.44556
